In this wave of biopharmaceuticals, it's really a case of "the early bird catches the worm." Akeso Biopharma was downgraded by Daiwa in one go, yet its stock price still turned around and rose—this resilience is somewhat laughable and frustrating. RemeGen is making steady progress with its innovative drugs going global, but the gains are just so-so, with sentiment entirely propped up by expectations. Alphamab Oncology's technical chart shows a "triangle breakout," but who dares to chase technical signals blindly now? Joinn Laboratories opened high and closed low, surging violently yesterday only to cool off abruptly today—short-term sentiment shifts rapidly. Ascletis Pharma soared yesterday but nearly halved today, giving off the vibe of a messy aftermath for innovative drugs. It's enough to make you feel schizophrenic, and holding the stock is like a daily adrenaline rush.